Aurelien Marabelle

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 299 publications

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2026

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

Journal: Journal for immunotherapy of cancer

Published: May 05, 2026

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 18, 2026

Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials.

Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials.

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 26, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale.

Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 25, 2025

Future approaches to immune base biomarkers.

Future approaches to immune base biomarkers.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 04, 2025

Future approaches to immune-based biomarkers.

Future approaches to immune-based biomarkers.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 04, 2025

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Journal: Journal of neuro-oncology

Published: November 25, 2025

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 19, 2025

Showing 1-12 of 299

Last Updated: 09/26/2026